Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 4 November 2021, 10:06 HKT/SGT
Share:
    

Source: Eisai
Eisai and Digital Garage, Inc. Jointly Launch "Onlab Bio Dementia (Open Network Lab BioHealth Dementia Innovation Challenge)"
A Collaborative Cultivation Program with Dementia-related Startups

TOKYO, Nov 4, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it launches the "Open Network Lab BioHealth Dementia Innovation Challenge (Onlab Bio Dementia)", a collaborative cultivation program jointly implemented with Digital Garage, Inc., with the aim of contributing to solving issues related to dementia and starts recruiting startups for teams to participate in the program. The program is designed to resolve various issues related to dementia with technology and science by promoting open innovation between startups and Eisai and DG, and to realize the Dementia Inclusive Society.

The program "Onlab Bio Dementia" calls for Japanese and global startups that wish to collaborate with Eisai and DG by utilizing their unique and outstanding technologies or services to solve issues related to dementia, such as brain health check and maintenance, disease awareness and testing, accurate diagnosis and confirming effectiveness of treatment (drug / non-drug), and providing care that contribute to the improvement of QOL (quality of life).

The program will help selected startups for the business growth related to dementia by combining Eisai and DG's assets, including Eisai's wealth of experience and knowledge in medicine creation activities and disease awareness activities in the field of dementia, DG's business development track record and experience in the digital domain such as AI, blockchain, and digital health, and the management know- how and mentoring that DG has acquired through its efforts to provide business support to and invest in startups such as "Onlab". In this program, Eisai and DG will implement the "Open Innovation Program" aiming to create consortium, business alliance, and investment by multiplying the technologies and services of startups with the resources of Eisai and DG, considering collaboration, and conducting demonstration experiments, etc. In addition, the "Accelerator Program" will provide mentoring by experts in various field to accelerate the business growth of startups in the seed and early stages.

Eisai has set its new medium-term business plan "EWAY Future & Beyond", where the perspective will be shifted from that of patients to The People or each consumer. In "EWAY Future & Beyond", with "empowering The People to realize their fullest life" as the vision, Eisai will utilize the latest digital technology such as AI and aim to remove the anxiety of "The People," with delivering not only pharmaceutical products but also solutions to The People. For this, Eisai is progressing to build the Eisai Universal Platform (EUP) which delivers packaged solutions in addition to pharmaceutical products through synergies between the technologies of various external partners and its own R&D. In this program, which is a collaboration between Eisai and DG, Eisai will expand its contribution to "The People" based on EUP, with acquiring the opportunity for investment and collaboration in addition to building a new network with startups.

Media Inquiries:
Public Relations Department
Eisai Co., Ltd.
+81-(0)3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
May 21, 2026 23:23 HKT/SGT
Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
Apr 21, 2026 19:52 HKT/SGT
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Mar 27, 2026 19:14 HKT/SGT
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
Mar 27, 2026 17:19 HKT/SGT
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
Mar 23, 2026 10:19 HKT/SGT
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
Mar 19, 2026 09:54 HKT/SGT
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
Mar 17, 2026 18:49 HKT/SGT
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
Mar 12, 2026 16:21 HKT/SGT
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
Mar 11, 2026 11:07 HKT/SGT
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
Mar 2, 2026 08:49 HKT/SGT
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
More news >>
 News Alerts
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: